相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Hsp90 molecular chaperone: an open and shut case for treatment
Laurence H. Pearl et al.
BIOCHEMICAL JOURNAL (2008)
Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma
David B. Solit et al.
CLINICAL CANCER RESEARCH (2008)
Targeting Hsp90: small-molecule inhibitors and their clinical development
Tony Taldone et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
First use of an oral Hsp90 inhibitor in patients (Pts) with solid tumors: Alvespimycin (A) administered QOD or Q
K. T. Flaherty et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience
A. Elfiky et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A Phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of the oral Hsp90 inhibitor SNX-5422
J. C. Bryson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
Edward L. Korn et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: A phase I Dose-Escalation study
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Inhibitors of the heat shock response: Biology and pharmacology
Marissa V. Powers et al.
FEBS LETTERS (2007)
Phase II trials published in 2002: A cross-specialty comparison showing significant design differences between oncology trials and other medical specialties
Laura C. Michaelis et al.
CLINICAL CANCER RESEARCH (2007)
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
David B. Solit et al.
CLINICAL CANCER RESEARCH (2007)
Chemotherapy for metastatic melanoma - Time for a change?
Helen J. Gogas et al.
CANCER (2007)
Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues
Swee Y. Sharp et al.
MOLECULAR CANCER THERAPEUTICS (2007)
A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer
Grzegorz S. Nowakowski et al.
CLINICAL CANCER RESEARCH (2006)
Development and validation of a liquid chromatography/tandem mass spectrometry method for the determination of the novel anticancer agent 17-DMAG in human plasma
Javier Moreno-Farre et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2006)
Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models
V Smith et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Phase I pharmacokinetic and pharmacodynarnic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies
U Banerji et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models
AM Burger et al.
ANTI-CANCER DRUGS (2004)
Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials
TK Eigentler et al.
LANCET ONCOLOGY (2003)
Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models
YL Chung et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors
A Kamal et al.
NATURE (2003)
Telomerase as a target for cancer immunotherapy
B Nguyen et al.
CANCER BIOLOGY & THERAPY (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Evaluation of response: new and standard criteria
P Therasse
ANNALS OF ONCOLOGY (2002)
Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system
CM Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1
MJ Egorin et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2001)
Prognostic factors in metastatic melanoma: A pooled analysis of Eastern Cooperative Oncology Group trials
J Manola et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
MR Middleton et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
